Standard BioTools Return On Tangible Equity 2010-2024 | LAB

Standard BioTools return on tangible equity from 2010 to 2024. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.

Standard BioTools Return On Tangible Equity 2010-2024 | LAB

Standard BioTools return on tangible equity from 2010 to 2024. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
Related Stocks
Company NameMarket
Cap
Tempus AI (TEM)$11.4B
Inspire Medical Systems (INSP)$5.9B
Hims & Hers Health (HIMS)$5B
Axonics (AXNX)$3.6B
IRhythm Technologies (IRTC)$2.7B
Enovis (ENOV)$2.6B
Privia Health (PRVA)$2.5B
Omnicell (OMCL)$2.3B
Azenta (AZTA)$2.2B
10x Genomics (TXG)$1.9B
Clover Health Investments (CLOV)$1.7B
Schrodinger (SDGR)$1.4B
Phreesia (PHR)$1.2B
Fulgent Genetics (FLGT)$589M
Butterfly Network (BFLY)$558M
Talkspace (TALK)$555M
Definitive Healthcare (DH)$500M
Health Catalyst (HCAT)$498M
Pulmonx (LUNG)$294M
SOPHiA GENETICS SA (SOPH)$230M
TruBridge (TBRG)$203M
American Well (AMWL)$135M
P3 Health Partners (PIII)$134M
EUDA Health Holdings (EUDA)$108M
HeartBeam (BEAT)$68M
Future Health ESG (FHLT)$65M
111 (YI)$59M
Zepp Health (ZEPP)$49M
SHL Telemedicine (SHLT)$45M
CareCloud (CCLD)$44M